Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03192488 · ClinicalTrials.gov registry record · Phase 4
Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
NCT03192488 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 13 participants.
The verdict
NCT03192488, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performance time trials, and repeated sprint performance time trials in the laboratory at a simulated altitude of 3000m (9900ft) after dosing with 10 mg of Cetirizine or a placebo in a repeated measures design.
Interventions
- DRUG Placebo oral capsule
- OTHER Hypoxia
- DRUG Cetirizine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2017-08-31 |
| Est. Completion | 2018-06-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03192488
The ClinicalTrials.gov registry entry for NCT03192488 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo oral capsule is the first listed.
NCT03192488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03192488 about?
NCT03192488 is a clinical study titled "Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia". This study seeks to determine whether a simple, single intervention of Cetirizine / Zyrtec® use can improve exercise performance of active individuals when acutely exposed to altitude. For this project, healthy subjects will perform steady state and progressive work rate exercise, endurance performa...
What is the current status of trial NCT03192488?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2017-08-31. Estimated completion is 2018-06-06.
What interventions are being tested in trial NCT03192488?
The interventions under investigation include: Placebo oral capsule (DRUG), Hypoxia (OTHER), Cetirizine (DRUG).
Who is sponsoring clinical trial NCT03192488?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.